Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 12/20 | 0.55 |
| ▸ | DRD4 | P21917 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.48 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4403508 | 0.93 | UTS2R (0.54) | UTS2RDRD4 | |
| SCHEMBL4402669 | 0.90 | UTS2R (0.58) | UTS2R | |
| SCHEMBL4408263 | 0.90 | UTS2R (0.56) | UTS2RDRD4MCHR1 | |
| SCHEMBL4408257 | 0.89 | DRD4 (0.51) | UTS2RDRD4 | |
| SCHEMBL4403534 | 0.88 | UTS2R (0.54) | UTS2RDRD4 | |
| SCHEMBL4402673 | 0.88 | UTS2R (0.47) | UTS2RDRD4 | |
| SCHEMBL4403516 | 0.84 | UTS2R (0.54) | UTS2R | |
| SCHEMBL647341 | 0.84 | UTS2R (0.52) | UTS2RDRD4MCHR1 | |
| SCHEMBL4405697 | 0.82 | GPR119 (0.52) | UTS2RKMT2AMCHR1 | |
| SCHEMBL648321 | 0.81 | UTS2R (0.56) | UTS2RDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174964-B2 | AMPK-activating piperidinyloxy-substituted 2,3-dihydro-1H-indene-1-amine compounds and pharmaceutical compositions including the same | RIGEL PHARMACEUTICALS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140051673-A1 | AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2014-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051673-A1 | AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same | PRKAA1, PRKAA2, PRKAG1 | UTS2R 1535/4885DRD4 4704/4885GAA 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.